title: ThioTEPA pharmacokinetics during intravesical chemotherapy: the influence of dose and volume of instillate on systemic uptake and dose rate to the tumour.
abstract: ThioTEPA is given intravesically in a variety of schedules to treat superficial bladder cancer. In this study, the influence of the dose of ThioTEPA and the volume of instillate on the dose rate to the tumour and the systemic uptake of ThioTEPA was investigated in eight patients with pTa or pTl disease. Each patient received four courses of ThioTEPA consisting of 30 mg of drug/30 ml of distilled water, 30 mg/60 ml, 60 mg/30 ml and 60 mg/60 ml. Blood and urine samples were obtained for 8 h following instillation, and ThioTEPA and TEPA levels were measured. The AUC(infinity) values (areas under the concentration-time curve, extrapolated to infinity) in plasma were approximately 2 factors higher at the two 60-mg doses. However, the AUC value in the bladder was nearly 70% higher when 60 mg of drug was instilled in 30 ml of distilled water as compared with 60 mg in 60 ml. Thus, by decreasing the volume of instillate it is possible to increase the dose rate to the tumour without increasing the systemic toxicity.
authors.affiliation: Institute of Urology and Nephrology, University College London, UK.
authors.forename: J R
authors.initials: JR
authors.lastname: Masters
authors.forename: B J
authors.initials: BJ
authors.lastname: McDermott
authors.forename: S
authors.initials: S
authors.lastname: Harland
authors.forename: M C
authors.initials: MC
authors.lastname: Bibby
authors.forename: P M
authors.initials: PM
authors.lastname: Loadman
mesh_terms: D000042:Absorption; D000283:Administration, Intravesical; D000368:Aged; D000704:Analysis of Variance; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000378:metabolism*; D013852:Thiotepa / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D013721:Triethylenephosphoramide / Q000097:blood / Q000652:urine; D001743:Urinary Bladder / Q000378:metabolism; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy / Q000378:metabolism*
chemical_list: D018906:Antineoplastic Agents, Alkylating; D013852:Thiotepa; D013721:Triethylenephosphoramide